Prescription Opioid Performance Improvement Metrics and Heroin Abuse

处方阿片类药物性能改进指标和海洛因滥用

基本信息

  • 批准号:
    9338109
  • 负责人:
  • 金额:
    $ 39.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Despite stabilizing rates of prescription opioid pain reliever (OPR) overdoses, opioid-related mortality continues to rise because of increasing rates of heroin use and poisoning. Between 2013 and 2014, national estimates of nonmedical use of OPRs in the previous year declined from 11.08 to 10.34 million individuals. In contrast, heroin use increased from 0.68 to 0.91 million individuals. Mortality from heroin increased 26% in the last year and more than 300% over the last five years. The shift in trend is more than ecologic, as 40% to 70% of individuals who use heroin report nonmedical use of an OPR prior to initiating heroin. This is a substantial departure from historical trajectories of heroin use. For the great majority of individuals who began heroin use in the 1960s, heroin was their first opioid. While the risk of transition to heroin from nonmedical use of OPRs is low, contributing and pre-disposing factors are poorly understood. The burden of OPR and heroin-related adverse events is particularly high for individuals in Medicaid programs because they are more likely to have substance use disorders and are disproportionately represented among overdose deaths. The state of Oregon recently developed a state Performance Improvement Project (PIP) to reduce the proportion of high-dose opioid prescriptions in its Medicaid program, which is now delivered through 16 regionally and health system defined Coordinated Care Organizations (CCOs). Because each CCO has flexibility to address the state's PIP, implementation across CCOs constitutes a natural experiment to study policy factors associated with change in OPR prescribing and heroin-related outcomes. In response to RFA-CE-16-003 (Research on Prescription Opioid Use, Opioid Prescribing, and Associated Heroin Risk; Priority #2), the objective of this study is to evaluate the relationships between OPR prescribing, CCO opioid dose reduction initiatives on patterns of OPR utilization, heroin use, and opioid-related overdoses. The objective is achieved through three Specific Aims using a mixed methods approach. First, using a multisource linked database that includes prescription drug monitoring program (PDMP), Medicaid claims, vital statistics, and substance use treatment data from Oregon, relationships between OPR prescribing patterns and heroin-related outcomes will be tested. Second, using qualitative research methods, policies and procedures directed at improving the statewide high dose PIP by each CCO will be characterized. Finally, the effect of implementation of CCO PIP initiatives on high-risk OPR use and heroin-related outcomes will be evaluated. Findings from this study will contribute to our understanding of individual risk factors for transition to and overdose with heroin. Also, knowledge gained will assist local and national decision makers about policy levers to reduce the burden of OPR and heroin- related morbidity and mortality.
摘要

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Patterns of Prescription Opioid Use Prior to Self-reported Heroin Initiation.
自我报告开始使用海洛因之前处方阿片类药物的使用模式。
  • DOI:
    10.1097/adm.0000000000000708
  • 发表时间:
    2021-04-01
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Hartung DM;Geddes J;Johnston KA;Leichtling G;Hallvik S;Hildebran C;Korthuis PT
  • 通讯作者:
    Korthuis PT
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel M Hartung其他文献

Effect of integration of prescription drug monitoring program data in the electronic health record on queries by primary care providers
将处方药监测计划数据整合到电子健康记录中对初级保健提供者查询的影响
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Daniel M Hartung;Steven Z Kassakian;Michelle A Hendricks
  • 通讯作者:
    Michelle A Hendricks
Sedative-hypnotic Co-prescribing with Opioids in a Large Network of Community Health Centers
大型社区卫生中心网络中镇静催眠药与阿片类药物的联合处方
  • DOI:
    10.1370/afm.20.s1.2660
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Daniel M Hartung;J. Lucas;N. Huguet;S. Bailey;J. O'Malley;Robert W. Voss;I. Chamine;J. Muench
  • 通讯作者:
    J. Muench

Daniel M Hartung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel M Hartung', 18)}}的其他基金

Prescription Drug Monitoring Program Integration in the Electronic Health Record
电子健康记录中的处方药监测计划集成
  • 批准号:
    10374016
  • 财政年份:
    2021
  • 资助金额:
    $ 39.87万
  • 项目类别:
Prescription Drug Monitoring Program Integration in the Electronic Health Record
电子健康记录中的处方药监测计划集成
  • 批准号:
    10196591
  • 财政年份:
    2021
  • 资助金额:
    $ 39.87万
  • 项目类别:
EpiCenter - EPIdemiology of opioid prescribing in community health CENTERs
EpiCenter - 社区卫生中心阿片类药物处方的流行病学
  • 批准号:
    10625654
  • 财政年份:
    2018
  • 资助金额:
    $ 39.87万
  • 项目类别:
Prescription Opioid Performance Improvement Metrics and Heroin Abuse
处方阿片类药物性能改进指标和海洛因滥用
  • 批准号:
    9225660
  • 财政年份:
    2016
  • 资助金额:
    $ 39.87万
  • 项目类别:
PDMP Toolkit
PDMP工具包
  • 批准号:
    9143141
  • 财政年份:
    2015
  • 资助金额:
    $ 39.87万
  • 项目类别:
PDMP Toolkit
PDMP工具包
  • 批准号:
    8999930
  • 财政年份:
    2015
  • 资助金额:
    $ 39.87万
  • 项目类别:
PDMP Toolkit
PDMP工具包
  • 批准号:
    9322275
  • 财政年份:
    2015
  • 资助金额:
    $ 39.87万
  • 项目类别:
Opioid Analgesic Policies and Prescription Drug Abuse in State Medicaid Programs
州医疗补助计划中的阿片类镇痛政策和处方药滥用
  • 批准号:
    8926884
  • 财政年份:
    2014
  • 资助金额:
    $ 39.87万
  • 项目类别:
Opioid Analgesic Policies and Prescription Drug Abuse in State Medicaid Programs
州医疗补助计划中的阿片类镇痛政策和处方药滥用
  • 批准号:
    8825191
  • 财政年份:
    2014
  • 资助金额:
    $ 39.87万
  • 项目类别:

相似海外基金

SBIR Phase I: Development of wearable medical device to detect and treat opioid overdose.
SBIR 第一阶段:开发可穿戴医疗设备来检测和治疗阿片类药物过量。
  • 批准号:
    2335577
  • 财政年份:
    2024
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Standard Grant
Molecular insights into the allosteric regulation of opioid receptors
阿片受体变构调节的分子见解
  • 批准号:
    DE240100931
  • 财政年份:
    2024
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Discovery Early Career Researcher Award
NSF Convergence Accelerator Track L: An Integrated and Miniaturized Opioid Sensor System: Advancing Evidence-Based Strategies for Addressing the Opioid Crisis
NSF 融合加速器轨道 L:集成和小型化阿片类药物传感器系统:推进解决阿片类药物危机的循证策略
  • 批准号:
    2344344
  • 财政年份:
    2024
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Standard Grant
Using multiple data sources to understand the opioid crisis in Australia
使用多个数据源了解澳大利亚的阿片类药物危机
  • 批准号:
    LP220100058
  • 财政年份:
    2024
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Linkage Projects
Multimodal opioid-sparing postoperative pain protocol versus standard of care for patients undergoing knee and shoulder arthroscopy: a randomized controlled trial and knowledge translation strategy
多模式阿片类药物保留术后疼痛方案与接受膝关节和肩关节镜检查的患者的护理标准:随机对照试验和知识转化策略
  • 批准号:
    485091
  • 财政年份:
    2023
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Operating Grants
Studies on the Treatment of Opioid Use Disorder in Pregnancy
妊娠期阿片类药物使用障碍的治疗研究
  • 批准号:
    489082
  • 财政年份:
    2023
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Operating Grants
Comparative effectiveness of medications for opioid use disorder among youth
青少年阿片类药物使用障碍药物治疗效果比较
  • 批准号:
    491317
  • 财政年份:
    2023
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Operating Grants
Unravelling the neural basis of breathing, respiratory depression, and analgesia by opioid drugs.
揭示阿片类药物呼吸、呼吸抑制和镇痛的神经基础。
  • 批准号:
    479039
  • 财政年份:
    2023
  • 资助金额:
    $ 39.87万
  • 项目类别:
    Operating Grants
Closed-loop attention bias modification brain training for opioid use disorder
针对阿片类药物使用障碍的闭环注意偏差修正大脑训练
  • 批准号:
    10699099
  • 财政年份:
    2023
  • 资助金额:
    $ 39.87万
  • 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
  • 批准号:
    10456380
  • 财政年份:
    2023
  • 资助金额:
    $ 39.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了